HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BO 3482

structure given in first source

Also Known As:

6-(1-hydroxyethyl)-2-((N-(2-hydroxyethyl)-N-methyl amino)thiocarbonylthio)-1-methyl-1-carbapen-2-em-3-carboxylate; BO-3482

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - beta-Lactams: 2386
      - Carbapenems: 4837
        BO 3482: 2
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - beta-Lactams: 2386
      - Carbapenems: 4837
        BO 3482: 2

Experts

1.	Abe, S: 1 article (06/2001)
2.	Hashizume, T: 1 article (06/2001)
3.	Ikeura, C: 1 article (06/2001)
4.	Imamura, H: 1 article (06/2001)
5.	Jona, H: 1 article (06/2001)
6.	Kiyonaga, H: 1 article (06/2001)
7.	Morishima, H: 1 article (06/2001)
8.	Moriya, M: 1 article (06/2001)
9.	Nagano, R: 1 article (06/2001)
10.	Nakano, M: 1 article (06/2001)

Related Diseases

1.	Infections 06/01/2001 - "As a result, we discovered a 1 beta-methyl-2-[4-(4-carbamoylmethyl-1,4-diazabicyclo[2,2,2]octanediium-1-yl)methyl-1,2,3,6-tetrahydropyridinylthiocarbonylthio]carbapenem, 14a showing greater than 2-fold better anti-MRSA activity in a mouse infection model and 3-fold better DHP-I susceptibility as compared with BO-3482 (1)." 10/01/1997 - "The potent in vivo activity of BO-3482-cilastatin against such MRSA infections can be ascribed to the good in vitro anti-MRSA activity and improved pharmacokinetics in mice when BO-3482 is combined with cilastatin and to the bactericidal nature of the carbapenem." 10/01/1997 - "The in vivo activity of BO-3482, which has a dithiocarbamate chain at the C-2 position of 1beta-methyl-carbapenem, was compared with those of vancomycin and imipenem in murine models of septicemia and thigh infection with methicillin-resistant Staphylococcus aureus (MRSA). "
2.	Sepsis (Septicemia) 10/01/1997 - "BO-3482 was also as effective as vancomycin in an MRSA septicemia model with mice with cyclophosphamide-induced immunosuppression. " 10/01/1997 - "In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem. " 10/01/1997 - "The in vivo activity of BO-3482, which has a dithiocarbamate chain at the C-2 position of 1beta-methyl-carbapenem, was compared with those of vancomycin and imipenem in murine models of septicemia and thigh infection with methicillin-resistant Staphylococcus aureus (MRSA). "
3.	Body Weight (Weight, Body) 10/01/1997 - "In the septicemia models, which involved two homogeneous MRSA strains and one heterogeneous MRSA strain, the 50% effective doses were, respectively, 4.80, 6.06, and 0.46 mg/kg of body weight for BO-3482; 5.56, 2.15, and 1.79 mg/kg for vancomycin; and >200, >200, and 15.9 mg/kg for imipenem. "

Related Drugs and Biologics

1.	Carbapenems (Carbapenem Antibiotics)
2.	Cilastatin
3.	Imipenem
4.	Vancomycin
5.	Cyclophosphamide (Cytoxan)